Chemical form of silicon determines its absorption and bioavailability: particulate and polymerized forms exhibit minimal oral bioavailability, while monomers (maltodextrin-stabilized orthosilicic acid, M-OSA) and organic compounds (monomethylsilanetriol, MMST) may hypothetically be highly absorbed. This study aimed to investigate the dermatological effects of oral ingestion of silicon, either solid (M-OSA–SiliciuMax^® Powder) or liquid (MMST, SiliciuMax^® Liquid) on the skin, hair and nails of healthy volunteers, through a clinical trial (Registry number 2,032,724. Full protocol at Plataforma Brasil website). Patients were randomized to receive 5 mg of elemental Si, either M-OSA or MMST (group 1 and 2, n = 17 each) or placebo (group 3, n = 17) twice a day for 150 days. Clinical and patients’ subjective evaluations were conducted. Multispectral face imaging and hair mineral analysis were also performed. Use of M-OSA and MMST provided significant (p < 0.05) betterment of facial wrinkles and UV spots. Changes were also observed at the end of the study in skin texture and length of eyelashes. Hair aluminum levels decrease with the treatments. Self-reported questionnaire indicated good satisfaction with both M-OSA and MMST. Continuous use of both M-OSA and MMST can provide improvements on skin parameters, as well as act as a detox agent for aluminum.

Orodispersible films (ODFs) are solid pharmaceutical forms for rapid local or systemic release of active ingredients. They are formed by a water-soluble polymer film that hydrates rapidly, adhering and dissolving immediately when placed on the tongue or in the oral cavity. In this paper, we describe the compatibility and disintegration times of compounded ODFs using OrPhyllo^TM, a new ready-to-use-vehicle, and APIs from different pharmacological classes, such as 5-hydroxytryptophan (5-HTP) 50 mg, bromopride 5 mg, coenzyme Q10 20 mg, melatonin 3 mg, resveratrol 5 mg, tadalafil 10 mg, vitamin B12 1 mg, or vitamin D3 2000 UI. ODFs were compounded and, subsequently, the samples were assayed using HPLC at initial (t = 0), 7 days (t = 7), 14 days (t = 14), 30 days (t = 30), 60 days (t = 60), 90 days (t = 90), 120 days (t = 120), 150 days (t = 150), and 180 days (t = 180) after compounding. Given the percentage of recovery of the APIs within the films, the beyond-use date of the final products (API + vehicle) was at least 90 days for vitamin D3, 150 days for bromopride and 5-HTP, and 180 days for coenzyme Q10, tadalafil, vitamin B12, resveratrol, and melatonin, when stored at room temperature. The average disintegration time was 46.22 s. This suggests that the OrPhyllo^TM vehicle is suitable for compounding ODFs with APIs from different pharmacological classes, with good compatibility and fast disintegration.